HER2 overexpressing metastatic breast cancer

[1]  K. Fujimoto-Ouchi,et al.  Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5′-dFUrd in human breast cancer models , 2002, Cancer Chemotherapy and Pharmacology.

[2]  M. Press,et al.  Improved survival benefit from Herceptin (trastuzumab) and chemotherapy in patients selected by fluorescence in situ hybridization. , 2001 .

[3]  J. Manola,et al.  Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  K S Panageas,et al.  Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  W. McCaskill-Stevens,et al.  Breast cancer prevention: the next steps. , 2000, European journal of cancer.

[6]  S. Goldstein,et al.  Update on raloxifene to prevent endometrial-breast cancer. , 2000, European journal of cancer.

[7]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Colozza,et al.  C-ERB-B2 expression as a predictor of outcome in a randomized trial comparing adjuvant CMF vs single-agent epirubicin in stage I-II breast cancer (BC) patients , 1999 .

[9]  M. Sliwkowski,et al.  Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers , 1999, Oncogene.

[10]  D A Berry,et al.  erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. , 1998, Journal of the National Cancer Institute.

[11]  D Tripathy,et al.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Finn,et al.  The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells , 1997, Oncogene.

[13]  D Tripathy,et al.  Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  F. Révillion,et al.  Plasma c-erbB2 concentrations in relation to chemotherapy in breast cancer patients. , 1996, European journal of cancer.

[15]  G. Smith,et al.  Current status of vinorelbine for breast cancer. , 1995, Oncology.

[16]  J. Foekens,et al.  Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. , 1995, Gene.

[17]  T. Delozier,et al.  Vinorelbine (Navelbine) in the treatment of breast cancer: the European experience. , 1995, Seminars in oncology.

[18]  M. Fernö,et al.  ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. , 1994, Cancer letters.

[19]  R Akita,et al.  Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. , 1993, Cancer research.

[20]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[21]  F. Hamdy,et al.  THE NEW ENGLAND JOURNAL OF MEDICINE , 1977, The Lancet.

[22]  M. Zelen,et al.  Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. , 1989, The New England journal of medicine.